The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: A clinical review

British Journal of Neurosurgery

Volumn 25, Issue 4, 2011, Pages 459-469

  Dixit, Sanjay ^a,b   Hingorani, Mohan ^a   Achawal, Shailendra ^b   Scott, Ian ^b  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

BCNU wafers; Carmustine wafers; Gliadel ; Glioblastoma; Temozolomide

Indexed keywords

CARBAMAZEPINE; CARMUSTINE; DEXAMETHASONE; PLACEBO; TEMOZOLOMIDE;

APLASTIC ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CONSTIPATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEALTH CARE COST; HUMAN; LIVER TOXICITY; META ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGICAL COMPLICATION; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUPP PROTOCOL; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DECANOIC ACIDS; DRUG IMPLANTS; GLIOBLASTOMA; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POLYESTERS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 79961190845     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2010.550342     Document Type: Review

References (36)

1. . 2007. Accessed 20 March 2010.
2. Anderson E, Grant R, Lewis SC, Whittle IR. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? Br J Neurosurg 2008; 22(3):339-49. (Pubitemid 351878617)
3. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5(2):79-88. (Pubitemid 36422560)
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96. (Pubitemid 40349501)
5. (www.nice.org.uk/TA121). 2007.
6. Pan E, Mitchell S, Tsai J. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neuro-Oncol 2008;88(3):353-7.
7. La Rocca R, Vitaz TW, Villanueva W, et al. A phase 2 study of multimodal therapy with surgery, carmustine (BCNU) wafer, radiation therapy (RT), and temozolomide (TMZ) in patients with newly diagnosed supratentorial malignant glioma (MG). Barcelona: EANO, 2008.
8. Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable Carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 2010;17(7):1740-6.
9. Affronti ML, Heery CR, II JEH, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009;115(15):3501-11.
10. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009; 110(3):583-8.
11. Ryken T, Carlisle T, Buatti J, et al. Treatment of adults with newly diagnosed glioblastoma multiforme or anaplastic astrocytoma with surgery, gliadel wafers and limited field radiation plus concomitant temozolomide followed by adjuvant temozolomide. J Clin Oncol 2008;26:abstr. 13003.
12. Asher AL. Prospective analysis of temozolomide as adjuvant to Gliadel and radiation in newly diagnosed malignant glioma [abstract]. American Association of Neurological Surgeons. Washington, DC: American Association of Neurological Surgeons, 75th Annual Meeting 2007: A42860.
13. Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010;33(4):441-9.
14. Noel G, Kehrly P, Schott R, et al. Adding biodegradable carmustine wafers before a stupp schedule does not alter outcome of patients with high grade brain tumor. Int J Radiat Oncol Biol Phys 2009;75(3):S247.
15. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148(3):269-75; discussion 275.
16. . 2009(version 3)
17. Perry J CA, Spithoff K, Laperriere N. Neuro-oncology Disease Site Group. Gliadel wafers in the treatment of malignant glioma: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO) (Evidence-based series; no. 9-7), 2006.
18. 5http://sircamt.canceraquitaine.org/rca/documents/referentiels/ RefGliomes.pdf4.
19. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 48-9.
20. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008;15(10): 2887-93.
21. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-66.
22. Gururangan S, Cokgor L, Rich JN, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol 2001;3(4):246-50. (Pubitemid 33674145)
23. Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 2008;24(11):3239-57.
24. Barrie M, Couprie C, Dufour H, et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 2005;16(7):1177-84. (Pubitemid 41418322)
25. Glas M, Happold C, Rieger J, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009;27(8):1257-61.
26. Susan MC, Wendy S, Walter C, et al. Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. Int J Radiat Oncol Biol Phys 2004;59(4): 1122-6.
27. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from Temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003. (Pubitemid 40349502)
28. Quinn JA, Jiang SX, Carter J, et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 2009;15(3):1064-8.
29. http://www.cancer.gov/search/ResultsClinicalTrials.aspx? protocolsearchid7346248. 2010.
30. Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 2009;27(8):1275-9.
31. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002;41(6):403-19. (Pubitemid 34753678)
32. Spiegel BM, Esrailian E, Laine L, Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 2007;21(9):775-87. (Pubitemid 47294722)
33. Sher D, Henson J, Avutu B, et al. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neuro-Oncol 2008;88(1):43-50.
34. La Rocca RV, Mehdorn HM. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin 2009;25(1):149-60.
35. Giese A, Bock HC, Kantelhardt SR, Rohde V. Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cen Eur Neurosurg. 2010;71(4):199-206.
36. www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf. January 2009 .http://www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf. January 2009